Comprehensive review of incretin-based diabetes therapy covering GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors — mechanism, efficacy, safety, and clinical positioning in T2DM management.
Key findingComprehensive review of incretin-based diabetes therapy covering GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors — mechanism, ef
What the researchers found
Comprehensive review of incretin-based diabetes therapy covering GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors — mechanism, efficacy, safety, and clinical positioning in T2DM management.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.
Diabetes, metabolic syndrome and obesity : targets and therapy, 3, 155-63
Citation
Hansen, Katrine B; Vilsbøll, Tina; Knop, Filip K. (2010). Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.. Diabetes, metabolic syndrome and obesity : targets and therapy, 3, 155-63.